Avisa Approves 5 New GLP-1 Pens for Obesity and Diabetes Treatment
6 Articles
6 Articles
Freepik The National Agency for Health Surveillance (Anvisa) has announced the approval of five new pens based on liraglutide and semaglutide, substances used in the treatment of diabetes and obesity. Of the authorized medicines, three are indicated for diabetes and two for weight control. With the new records, scheduled for publication this Thursday (29), the number of pens of this class approved by the agency in 2026 reaches 20. The drugs belo…
According to the agency, 3 medications are indicated for diabetes and 2 for obesity treatment. Read on Power360.
The National Agency for Health Surveillance (Anvisa) approved, on Thursday (29), the registration of five new pens applying drugs based on liraglutide and semaglutide, substances used in the treatment of diabetes and obesity. According to information released by Metropolis on Thursday (29), the decision was published by Resolution No. 4.244/2026 in the Diário [...]
New options with liraglutide and semaglutide arrive to expand the treatments in the country and strengthen the supply of these remedies by SUS
Five new GLP-1 slimming and diabetes pens were approved by the National Agency for Health Surveillance (Anvisa) on Thursday, 29.Three of these drugs are indicated for the treatment of diabetes and two for the treatment of obesity.In total, Anvisa has already approved 20 pens this year.Beginned in August 2025, the prioritization of the analysis of medicines with semaglutide and liraglutide was motivated by the request of the Ministry of Health fo…
With the new referrals, Anvisa adds 20 slimming and antidiabetic pens approved throughout the year 2026
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
